Microcap Ledger Alector, Inc. $ALEC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 111,656,919 [10-Q 2026-08-06]
What the company doesAI summary of filing
Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. The company's lead candidate, nivisnebart, is a monoclonal antibody designed to elevate progranulin levels in the brain for the treatment of Alzheimer's disease and is currently in a Phase 2 clinical trial conducted with partner GlaxoSmithKline (GSK), with whom Alector shares development costs and potential profits. Alector is also advancing a portfolio of preclinical programs, including antibody therapies for amyloid-beta and glucocerebrosidase deficiency, and siRNA therapeutics targeting tau, alpha-synuclein, and NLRP3, all leveraging its proprietary Alector Brain Carrier (ABC) blood-brain barrier delivery platform. The company does not currently generate revenue from product sales and relies on third-party manufacturers and its partnership with GSK for development and commercialization. [10-K 2026-02-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $4.37M | −$45.92M | −$84.03M | $59.91M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $21.05M | −$143.00M | −$184.03M | $65.80M | [10-K 2026-02-25] |
| FY ended Dec 2024 | $100.56M | −$119.00M | −$229.91M | $33.02M | [10-K 2026-02-25] |
- Quarterly cash burn
- −$42.02M
- Cash runway Estimate
- ~4.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 97,932,605 | [10-Q 2024-11-06] |
| 2025-02-21 | 99,085,888 | [10-K 2025-02-26] |
| 2025-05-02 | 99,992,600 | [10-Q 2025-05-08] |
| 2025-08-01 | 101,212,329 | [10-Q 2025-08-07] |
| 2025-10-31 | 109,151,472 | [10-Q 2025-11-06] |
| 2026-02-20 | 110,362,581 | [10-K 2026-02-25] |
| 2026-05-01 | 111,025,187 | [10-Q 2026-05-07] |
| 2026-07-31 | 111,656,919 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-03-12; declared effective 2026-04-30 [S-3 2026-03-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-04 | Wong-Sarad Grace | sell | 3,625 | $2.51 | [4 2026-09-04] |
| 2026-09-03 | Wong-Sarad Grace | sell | 5,165 | $2.67 | [4 2026-09-04] |
| 2026-09-03 | Berkley Neil Lindsay | sell | 29,251 | $2.66 | [4 2026-09-04] |
| 2026-09-03 | Rosenthal Arnon | sell | 72,606 | $2.66 | [4 2026-09-04] |
| 2026-09-02 | Wong-Sarad Grace | sell | 656 | $2.75 | [4 2026-09-04] |
| 2026-08-19 | Rosenthal Arnon | other | 1,050,000 | — | [4 2026-08-21] |
| 2026-08-19 | Rosenthal Arnon | other | 350,000 | — | [4 2026-08-21] |
| 2026-08-19 | Rosenthal Arnon | other | 350,000 | — | [4 2026-08-21] |
| 2026-08-19 | Rosenthal Arnon | other | 350,000 | — | [4 2026-08-21] |
| 2026-07-09 | Wong-Sarad Grace | grant | 20,000 | — | [4 2026-07-09] |
| 2026-06-17 | Yaffe Kristine | grant | 28,700 | — | [4 2026-06-17] |
| 2026-06-17 | Scheller Richard H | grant | 28,700 | — | [4 2026-06-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Material agreement entered; Results of operations; Regulation FD disclosure |
| 2026-09-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-08 | 8-K | Material agreement terminated |
| 2026-06-17 | 8-K | Shareholder vote results |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 8-K | Material agreement entered |
| 2026-05-07 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
Alerts for $ALEC
Email me when Alector, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.